


PATENT
Docket No. 432722002601

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EL719395220US

Date of Deposit: January 15, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.


Rhea Amid

J1000 U.S.P.T.O.
10/050425
01/15/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Gregory R. MUNDY et al.

Serial No.: To be assigned

Continuation of Serial No. 09/361,775

Filing Date: Herewith

For: INHIBITORS OF PROTEASOMAL
ACTIVITY FOR STIMULATING HAIR
GROWTH

Examiner: To be assigned

Group Art Unit: To be assigned

PETITION TO MAKE SPECIAL UNDER MPEP 708.03 XII

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

1. The present application is a continuation of the parent application Serial No. 09/361,775, which has been assigned to OsteoScreen, Inc. via an assignment recorded as reel/frame 010323/0868, a copy of which is enclosed herewith (Exhibit A). OsteoScreen, Inc. is a corporation of Texas entitled to small entity status. A declaration of small entity status executed by Gregory R. Mundy in connection with the parent application is also enclosed herewith (Exhibit B).

02/07/2002 YGIZAW 00000001 031952 10050425

01 FC:122 130.00 CH

sd-74344

2. The subject of the patent application is a major asset of OsteoScreen, Inc.
3. The development of the technology set forth in the application, which is critical to OsteoScreen, Inc. and which is of significance to biotechnology, will be significantly impaired if examination of the patent application is delayed.

4. The petition fee under 37 C.F.R. 1.17(i) is enclosed.

Explanation (MPEP 708.03, XII, c) of the basis for statement 3:


The present application relates to a technology which has the potential for significantly advancing the treatment of hair loss associated diseases or disorders. Hair loss associated diseases or disorders, *e.g.*, male pattern baldness, alopecia caused by chemotherapy, hair thinning due to aging, and genetic disorders, are prevalent and new treatment is needed. The treatment technology disclosed and claimed in the present application is a major asset of OsteoScreen, Inc. and will be the technological foundation of a new small entity corporation, which will be dedicated to the further development and commercialization of the treatment technology. The financing and formation of the new small entity will be made impossible or be severely impaired without assurance that the application will be quickly examined.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the

filing of this document to **Deposit Account No. 03-1952** referencing 432722002601. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: January 15, 2002

Respectfully submitted,

By: 
Peng Chen
Registration No. 43,543

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5117
Facsimile: (858) 720-5125